<DOC>
	<DOCNO>NCT01737879</DOCNO>
	<brief_summary>The purpose study evaluate whether hemodialysis patient peginesatide convert epoetin alfa use predefined conversion table achieve stable hemoglobin .</brief_summary>
	<brief_title>Evaluation Conversion From Peginesatide Epoetin Alfa Patients Receiving Hemodialysis</brief_title>
	<detailed_description>This phase 4 , multicenter , single-arm , open-label study design evaluate whether patient receive hemodialysis treat peginesatide convert epoetin alfa use predefined conversion table achieve stable hemoglobin . The study conduct two phase . Hemodialysis patient treat epoetin alfa 3 time week ( TIW ) first convert peginesatide administer every 4 week ( Q4W ) . After 24 week , participant convert back epoetin alfa administer TIW 32 week . The primary endpoint mean hemoglobin last 8 week epoetin alfa period .</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Key Receiving hemodialysis 3 time week Receiving epoetin alfa IV 3 time week Hemoglobin concentration ≥ 9.0 ≤ 12.0 g/dL within 8 week screen Key Systemic hematologic disease Changes Epoetin alfa dose ≥ 50 % within 8 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Anemia , Chronic Kidney Disease , End Stage Renal Disease , erythropoiesis-stimulating agent , Hemodialysis , Hemoglobin</keyword>
</DOC>